糖尿病新世界2024,Vol.27Issue(9) :187-189,194.DOI:10.16658/j.cnki.1672-4062.2024.09.187

度拉糖肽治疗糖尿病视网膜病变对患者血糖及视力水平的影响

Effect of Ditaranotide Treatment of Diabetic Retinopathy on Blood Glu-cose and Vision Level

李萌 蔡泽淮 张丹
糖尿病新世界2024,Vol.27Issue(9) :187-189,194.DOI:10.16658/j.cnki.1672-4062.2024.09.187

度拉糖肽治疗糖尿病视网膜病变对患者血糖及视力水平的影响

Effect of Ditaranotide Treatment of Diabetic Retinopathy on Blood Glu-cose and Vision Level

李萌 1蔡泽淮 1张丹1
扫码查看

作者信息

  • 1. 四川大学华西厦门医院(研究院),福建 厦门 361000
  • 折叠

摘要

目的 探究度拉糖肽治疗糖尿病视网膜病变对患者血糖及视力水平的影响.方法 回顾性选取四川大学华西厦门医院(研究院)于2022年5月—2023年7月收治的140例糖尿病视网膜病变患者的临床资料,根据治疗药物不同分为对照组(n=70)、研究组(n=70).对照组行阿卡波糖治疗,研究组皮下注射度拉糖肽治疗.对比两组临床疗效及不良反应,比较两组治疗前后的血糖水平[空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2-hour postprandial plasma glucose,2-hPG)]、视力水平[裸眼视力、黄斑厚度及出血斑面积].结果 治疗后,研究组疗效优于对照组,差异有统计学意义(P<0.05).研究组FPG、2 hPG水平低于对照组,差异有统计学意义(P<0.05).研究组视力水平较高于照组,差异有统计学意义(P<0.05).两组不良反应发生率对比,差异无统计学意义(P>0.05).结论 度拉糖肽在治疗糖尿病视网膜病变中能够降低血糖水平、改善视力水平、提高临床疗效,且不良反应发生率较低.

Abstract

Objective To explore the effect of durapeptide treatment of diabetic retinopathy on blood glucose and vi-sion level.Methods The clinical data of a total of 140 patients from May 2022 to July 2023 in the West China Xia-men Hospital of Sichuan University(Research Institute)were retrospectively analyzed,which were divided into(n=70)and study group(n=70)according different therapeutic drugs.The study group received subcutaneous durarantide in-jection.The clinical efficacy and adverse reactions of the two groups were compared.Before and after treatment,the blood glucose level[fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG)],visual acuity level[naked eye vision,macular thickness bleeding spot area].Results After treatment,the therapeutic effect of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).The levels of FPG and 2 hPG in the study group were lower than those in the control group,and the differences were statistically sig-nificant(both P<0.05).The visual acuity of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse effects of the two groups(P>0.05).Conclusion Dragycopeptide can reduce blood glucose level,improve visual level and improve clini-cal efficacy in the treatment of diabetic retinopathy,and the risk of adverse reactions is relatively low.

关键词

度拉糖肽/糖尿病视网膜病变/血糖/视力水平/不良反应

Key words

Dereptide/Diabetic retinopathy/Blood glucose/Vision level/Adverse effects

引用本文复制引用

出版年

2024
糖尿病新世界
中国病理生理学会

糖尿病新世界

影响因子:0.461
ISSN:1672-4062
参考文献量10
段落导航相关论文